Search Results

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”) today announced that it entered into a collaboration agreement with SIGA Technologies (Nasdaq: SIGA) in the first quarter of 2024, to support the development of Calidi’s systemic and targeted RTNova (CLD-400) virotherapy platform, which has the potential to provide a universal treatment for all tumor types.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on global health and infectious diseases, announced an agreement to expand access to TPOXX to the member states in the Association of Southeast Asian Nations, a political and economic union in the region.

Oral doses of SIGA Technologies’ antiviral drug Tpoxx will help the U.S. maintain its reserves of the vaccine in preparation for future potential outbreaks, according to the company.

SIGA Technologies, Inc. announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, May 7, 2024.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, reported financial results for the three months ended March 31, 2024.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the appointment of Larry Miller as general counsel.

SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2023.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on health security and infectious disease, announced that it entered into an amendment to its international promotion agreement with Meridian Medical Technologies, Inc.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, announced that its board of directors declared a special cash dividend of $0.60 per share on the company’s common stock.